![]() |
![]() |
![]() |
![]() |
PO5-1 | Association of liver fibrosis with emerging extrahepatic cancer in fatty liver patients with the PNPLA3 I148M GG genotype: an 8-year cohort study | MINGLING CHANG | ![]() |
![]() |
|||
PO4-1 | Diagnosing metabolic associated steatotic liver disease in primary care patients with type 2 diabetes mellitus - a novel, algorithm based approach | Damien Leith | ![]() |
![]() |
|||
PO7-1 | Association between cardiovascular disease risk factors and metabolic dysfunction-associated steatotic liver disease among rheumatoid arthritis patients | Alina Saidi | ![]() |
![]() |
|||
PO3-1 | PNPLA3 is associated to FIB-4 but not to (cardiovascular) mortality in an elderly population: report from the PROSPER trial | Vivian de Jong | ![]() |
![]() |
|||
PO1-1 | DMF-activated Nrf2 ameliorates palmitic acid toxicity in hepatocytes while potentiates ferroptosis: independent protection by NO-donors | Diana Abu halaka | ![]() |
![]() |
|||
PO2-1 | Low implementation rates of the American Gastroenterology Association (AGA) clinical care pathway in gastroenterology practice. | Pollard Nina | ![]() |
![]() |
|||
PO6-1 | A 5 sit-to-stand test may identify MASLD patients at higher risk for worse clinical outcomes | Roberta Forlano | ![]() |
![]() |
|||
PO2-2 | Efficacy of metabolyteTM treatment for MASH prevention and reversal | Giulia Angelini | ![]() |
![]() |
|||
PO5-2 | The correlation between the LDL level and the development of NAFLD | MOHAMED SHAFI MAHBOOB ALI | ![]() |
![]() |
|||
PO4-2 | Diabetic advanced steatotic liver disease is a surrogate for the other complications of type 2 diabetes mellitus | Zülal Istemihan | ![]() |
![]() |
|||
PO1-2 | The impact of artificial intelligence on the evaluation of fibrosis changes in steatotic liver diseases: a single center experience | Reha Akpinar | ![]() |
![]() |
|||
PO3-2 | Steatotic liver disease and risk of hepatocellular carcinoma in hepatitis B and C infected individuals: a systematic review and meta-analysis | Muhammed Elfaituri | ![]() |
![]() |
|||
PO7-2 | Lobular inflammation, but no NAS score, is associated with higher risk of progression to cirrhosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) | Giordano Sigon | ![]() |
![]() |
|||
PO4-3 | The PNPLA3 genotype of MASLD patients profoundly alters their metabolic profile even with a low BMI | Lina Jegodzinski | ![]() |
![]() |
|||
PO6-3 | Association between hepatic artery resistance index (HARI), portal venous pulsatility index (PVPI) and steatotic liver disease (SLD) fibrotic score in SLD patients | Simu Razvan-Ioan | ![]() |
![]() |
|||
PO2-3 | RIPK3 modulates acyl chain structure in metabolic liver disease | André Cardador | ![]() |
![]() |
|||
PO7-3 | Disruption of hepatic integrity and lipid composition by hypercaloric diets in steatotic liver disease | Maria Joao Meneses | ![]() |
![]() |
|||
PO3-3 | Shared genetics between NAFLD and Parkinsons disease: the role of TLR4 signaling pathway | Christina Flourou | ![]() |
![]() |
|||
PO1-3 | The effects of vitamin E and docosahexaenoic acid ethyl ester on nonalcoholic fatty liver disease (NAFLD) - a randomized double blind placebo controlled parallel group clinical trial (PUVENAFLD) | Naim Alkhouri | ![]() |
![]() |
|||
PO5-3 | Impact of exercise training on hepatic lipid composition in men with MASLD and impaired glycaemic regulation: a pilot randomised controlled trial | Sundus Malaikah | ![]() |
![]() |
|||
PO1-4 | The long term safety and efficacy of Saroglitazar in metabolic dysfunction-associated steatohepatitis (MASH) related compensated cirrhosis: a prospective, single center real life experience | Sujit Chaudhuri | ![]() |
![]() |
|||
PO6-4 | miR-21-5p promotes MASH-related hepatocarcinogenesis | Pedro Miguel Rodrigues | ![]() |
![]() |
|||
PO5-4 | Assessing hepatocellular senescence in metabolic dysfunction-associated liver disease using a quantitative approach | Roberta Forlano | ![]() |
![]() |
|||
PO3-4 | The natural history of metabolic dysfunction-associated steatotic liver disease with advanced fibrosis | Zouhir Gadi | ![]() |
![]() |
|||
PO7-4 | Liver steatosis and fibrosis in severe obesity in diabetic and non-diabetic subjects: first report of the Franciscus obesity NASH Study | Willy Theel | ![]() |
![]() |
|||
PO4-4 | Genetic markers of MASLD in an elderly Caucasian population and the association with obesity | Willy Theel | ![]() |
![]() |
|||
PO7-5 | Thermoacoustic assessment of fatty liver disease - a clinical feasibility study | Michael Thornton | ![]() |
![]() |
|||
PO4-5 | Single-cell profiling of hepatic dendritic cells in metabolic dysfunction-associated steatotic liver disease | Camilla Klaimi | ![]() |
![]() |
|||
PO6-5 | Changes in lipid metabolism and insulin resistance after an oral lipid load in patients with metabolic dysfunction associated steatotic liver disease (MASLD) carrying the PNPLA3 rs738409 polymorphism | Chiara Rosso | ![]() |
![]() |
|||
PO1-5 | Open data, explainable AI, data science and conventional NITs the recipe for new machine learning diagnostic tests on MASLD | Athanasios Angelakis | ![]() |
![]() |
|||
PO2-5 | Steatotic liver disease and SGLT2 inhibitors: improvement of hepatic fibrosis by Fibroscan in a prospective study | Jaqueline Curra | ![]() |
![]() |
|||
PO5-5 | Transcriptomics driven metabolic pathway analysis to explore metabolic resemblance between metabolic-dysfunction associated steatohepatitis mouse models and human | Mojgan Masoodi | ![]() |
![]() |
|||
PO6-6 | Analytical and clinical comparison of three non-invasive tests for the diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) | Silvia Sabatini | ![]() |
![]() |
|||
PO1-6 | Validation of HeparDx score (by Metadeq, Inc.) as a non-invasive test for the diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) | Giulia Angelini | ![]() |
![]() |
|||
PO7-6 | Risk factors for progression in metabolic dysfunction-associated steatotic liver disease | Letitia Toma | ![]() |
![]() |
|||
PO4-6 | Unleashing the potential of phytocannabinoids in modulating sphingolipid homeostasis for the treatment of metabolic dysfunction-associated steatotic liver disease | Radka Kocvarova | ![]() |
![]() |
|||
PO2-7 | Transcriptomics-assisted phenotypic screening to identify novel drugs and targets for liver fibrosis | Elisabetta De Filippo | ![]() |
![]() |
|||
PO1-7 | Poor diet quality is associated with higher liver stiffness and higher cardiovascular risk in a cohort of Italian MASLD (metabolic dysfunction associated steatotic liver disease) outpatients | Rusi Chen | ![]() |
![]() |
|||
PO7-7 | Quantitative assessment of liver steatosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) based on plasma extracellular vesicles in correlation with ultrasound attenuation parameter (UAP). | Eleni Myrto Trifylli | ![]() |
![]() |
|||
PO5-7 | Hypoxanthine plasma levels as a new potential non-invasive biomarker of metabolic-dysfunction associated steatotic liver disease | Melissa Maria Milito | ![]() |
![]() |
|||
PO4-7 | MASLD and chronic viral hepatitis: baseline results from patients enrolled in the PITER HCV and HBV and HDV italian cohorts | Loreta A. Kondili | ![]() |
![]() |
|||
PO3-7 | Behavioural specifics of patients living with non-alcoholic fatty liver disease/metabolic dysfunction-associated steatotic liver disease a key to improve communication | Andreas Geier | ![]() |
![]() |
|||
PO6-7 | The association of liver fibrosis, insulin resistance and systemic leukocyte activation in obese patients | Alina Saidi | ![]() |
![]() |
|||
PO4-8 | Comparison of the efficacy of MR spectroscopic and MR imaging methods for assessing liver fat changes in obese patients undergoing dietary intervention and GLP-1 agonist treatment | Petr Kordac | ![]() |
![]() |
|||
PO2-8 | Statin treatment reduces all-cause mortality in elderly with increased risk of liver fibrosis: report from the PROSPER trial | Vivian de Jong | ![]() |
![]() |
|||
PO5-8 | Assessment of liver fibrosis in individuals with inflammatory bowel disease and steatotic liver disease using non-invasive tests | Robert Nastasa | ![]() |
![]() |
|||
PO1-8 | Galectin-3 inhibitor prevents metabolic dysfunction-association steatohepatitis and insulin resistance in western diet-fed ApoE knockout mice | Layanne Araujo | ![]() |
![]() |
|||
PO6-8 | The potential role of Omentin-1 in metabolic-dysfunction associated steatotic liver disease (MASLD): evidence from translational studies | Noel Salvoza | ![]() |
![]() |
|||
PO7-8 | Novel compound SNP-6 series active metabolites mitigate nonalcoholic steatohepatitis and fibrosis: results from preclinical models and a phase 2a clinical trial | Chang-Hui Tsao | ![]() |
![]() |
|||
PO3-8 | Culturally adapting the mediterranean diet for the hispanic and latino population in the weight intervention in liver disease (WILD) clinical pathway | Sheena Gillani | ![]() |
![]() |
|||
PO4-9 | Gender differences in the development of steatotic liver disease and fibrosis: implications for diagnosis and management | Florian Koutny | ![]() |
![]() |
|||
PO5-9 | SMAD 3 variant rs10152544 is associated with higher fibrosis grade in metabolic steatotic liver disease (MASLD) | Claudia Oliveira | ![]() |
![]() |
|||
PO3-9 | Staging chronic liver injury and fibrosis using the enzyme biomarkers circulating fibroblast activation protein alpha (cFAP) and cDPP4 | Mark Gorrell | ![]() |
![]() |
|||
PO6-9 | The impact of sarcopenia on both liver and cardiovascular alterations in patients with early stages of steatotic liver disease: a sole protagonist or a co-actor with other metabolic risk factors? | FLORIANA SANTOMENNA | ![]() |
![]() |
|||
PO7-9 | Clinical and biochemical features of diagnosed and undiagnosed patients with non-alcoholic fatty liver disease | Julia Uhanova | ![]() |
![]() |
|||
PO1-9 | Pharmacodynamics screening of potential therapeutic substances in an experimental model of metabolic dysfunction associated steatohepatitis | Mahak Arora | ![]() |
![]() |
|||
PO2-9 | Assessing the repeatability and reproducibility of LiverMultiScan metrics cT1 and PDFF | Andrea Dennis | ![]() |
![]() |
|||
PO6-10 | A randomized controlled trial of Resmetirom in nonalcoholic steatohepatitis: 52-week Data From MAESTRO-NASH | Peter Rydqvist | ![]() |
![]() |
|||
PO5-10 | Histological features distinguish alcoholic from metabolic dysfunction-associated steatohepatitis | Tessa Ostyn | ![]() |
![]() |
|||
PO4-10 | Treatment with semaglutide affects favorably hepatic fat content but has no effect on response of liver fat to glucose and/or fructose administration | Jan Kovar | ![]() |
![]() |
|||
PO2-10 | Hepatic steroids metabolism reflects the entity of liver damage in patients with metabolic dysfunction-associated steatohepatitis (MASH) | Eleonora Dileo | ![]() |
![]() |
|||
PO1-10 | Persons diagnosed with metabolic dysfunction-associated steatotic liver disease are at an increased risk of severe depression in a Swedish nationwide cohort study | Hanne ström | ![]() |
![]() |
|||
PO7-10 | GCKIII kinases in hepatocellular lipotoxicity: role in NAFLD and beyond | Margit Mahlapuu | ![]() |
![]() |
|||
PO3-10 | Serum protein induced by vitamin k absence or antagonist II for the prediction and risk stratification of HCC development in patients with metabolic dysfunction-associated steatotic liver disease on long-term follow-up | Marta Guariglia | ![]() |
![]() |
|||
PO3-11 | Alcohol overconsumption is common in MASLD and highly increases risk for future cirrhosis | Hannes Hagström | ![]() |
![]() |
|||
PO1-11 | Cytokines level during the pregnancy with MASH and obesity under the developed complex therapy program | Lina Bahniy | ![]() |
![]() |
|||
PO4-11 | In silico strategies and gene expression data indicate EFEMP1 as a potential biomarker for early fibrosis diagnosis in metabolic dysfunction-associated steatotic liver disease | Allen Anthony Larańo | ![]() |
![]() |
|||
PO6-11 | The beneficial hepatic-effect of Glucagon-like Peptide 1 receptor agonists in diabetic patients with metabolic dysfunction-associated liver disease (MASLD) | Giordano Sigon | ![]() |
![]() |
|||
PO5-11 | Exploring the association between quality of life, diet, physical activity, and binge eating disorder in MASLD patients in a tertiary centre of care | Giordano Sigon | ![]() |
![]() |
|||
PO7-11 | Genetic evidence for a role of PON2 in liver fibrosis and generation of PON2 knockdown LX-2 cells | Tammy Huybrechts | ![]() |
![]() |
|||
PO2-11 | Adherence to mediterranean diet reduces steatotic liver disease risk but does not affect liver fibrosis assessed by transient elastography: results from a prospective study | Gediz Dogay Us | ![]() |
![]() |
|||
PO3-12 | Traditional indigenous land-based diet and non-alcoholic fatty liver disease | Julia Uhanova | ![]() |
![]() |
|||
PO7-12 | Glutamyl aminopeptidase A (APA): a novel secreted kidney protein impacting liver homeostasis | Sharleen Hamad | ![]() |
![]() |
|||
PO5-12 | Evaluation of non-invasive scores for monitoring liver fibrosis resolution after bariatric surgery | Francois Pattou | ![]() |
![]() |
|||
PO2-12 | Comparison of the prognosis of patients with metabolic dysfunction-associated steatotic liver disease and alcohol-related liver disease who underwent hepatic vein catheterization | imon Dostál | ![]() |
![]() |
|||
PO1-12 | Maternal overnutrition and increased risk of intergenerational liver disease and cancer targeting epigenetic mechanisms | Claudia Bigas | ![]() |
![]() |
|||
PO6-12 | Association between FAST score and hepatocyte ballooning in Non- Alcoholic steatohepatitis patients: findings from EVIDENCES-X study of 393 biopsied individuals | Deven Parmar | ![]() |
![]() |
|||
PO2-13 | Progression to cirrhosis and all-cause mortality is increased In postmenopausal women with MASLD independently of fibrosis stage at baseline | Aleksandra Dunin-Borkowska | ![]() |
![]() |
|||
PO4-13 | Low number needed to screen for advanced MASLD fibrosis in internal medicine and general practice | Koen van Son | ![]() |
![]() |
|||
PO5-13 | Early prediction of progressive fibrogenesis in participants with MASLD using blood-based biomarkers | Koen van Son | ![]() |
![]() |
|||
PO6-13 | Estimated glucose disposal rate correlates with histological severity of MASLD in women, but not in men | Zouhir Gadi | ![]() |
![]() |
|||
PO7-13 | Validation of the enhanced liver fibrosis (ELF)-test in heparinized and EDTA plasma for future reflex testing in diagnostic algorithms | Koen van Son | ![]() |
![]() |
|||
PO3-13 | CTRP1, a novel molecular linker for hepatic glycogen and lipid metabolism ameliorates fatty liver diseases | Sora Han | ![]() |
![]() |
|||
PO1-13 | Inflammatory landscape and metabolic profiling of the Mc4r KO mouse on a western diet to study human metabolic dysfunction associated steatohepatitis | Fabienne Birrer | ![]() |
![]() |
|||
PO7-14 | Cholesterol exacerbates microcirculatory abnomalities in non-alcoholic fatty liver disease | Evelyn Pereira | ![]() |
![]() |
|||
PO3-14 | Associations of the fibrosis-4 index with rates of cardiac events and liver decompensation, and the potential implications on risk stratification in patients with nonalcoholic steatohepatitis | Fishman Jesse | ![]() |
![]() |
|||
PO6-14 | Phosphatilylethanol probe into the de-novo post-liver transplant steatotic liver disease: MASLD, or MetALD? | Lubomir Skladany | ![]() |
![]() |
|||
PO5-14 | Impact of a 6-month dietary intervention on cognitive dysfunction and liver status in overweight/obese patients with metabolic dysfunction-associated steatotic liver disease | Nuria Pérez Diaz del Campo | ![]() |
![]() |
|||
PO2-14 | Loss of liver adrenoceptor alpha-1b exacerbates fibrosis and inflammation in mice | Bernie Efole | ![]() |
![]() |
|||
PO4-14 | Apolipoprotein F deficiency is associated with reduced mitochondrial function in hepatocytes | Viktor LIENARD | ![]() |
![]() |
|||
PO1-14 | Association of hepatic fibrosis and chronic kidney disease in a real world cohort of metabolic-dysfunction associated steatotic liver disease (MASLD); implications for screening in an intelligent LFT (iLFT) platform | Paul Brennan | ![]() |
![]() |
|||
PO1-15 | STE20-type Kinases MST3 and MST4 promote the progression of hepatocellular carcinoma | Mara Caputo | ![]() |
![]() |
|||
PO2-15 | Hepatocellular loss of mTOR aggravates tumor burden in non-alcoholic steatohepatitis-related HCC | Antje Egners | ![]() |
![]() |
|||
PO6-15 | Diagnostic accuracy and optimal cut-off of fibroScan controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) in assessing steatosis and fibrosis in patients with bariatric surgery and elective laparoscopic cholecystectomy | Riham Soliman | ![]() |
![]() |
|||
PO5-15 | Metabolomics analysis showed increased metabolites and acylcarnitine concentrations before and after a lipid load in subjects with steatotic liver disease | SAMANTHA PEZZICA | ![]() |
![]() |
|||
PO4-15 | Multiparametric liver ultrasound for non-invasive quantification of steatosis, fibrosis, ballooning and inflammation in metabolic dysfunction-associated steatotic liver disease | Antonio Liguori | ![]() |
![]() |
|||
PO3-15 | Mechanisms underlying steatotic liver disease in mental illness: antipsychotic drugs disrupt ferroptosis signaling pathways | Karen Houseknecht | ![]() |
![]() |
|||
PO6-16 | Steatotic liver disease and inflammatory bowel disease: is it all MASLD? | Patricia Sousa | ![]() |
![]() |
|||
PO3-16 | Serum free fatty acids in children with metabolic-associated fatty liver fibrosis | Nataliya Zavhorodnia | ![]() |
![]() |
|||
PO4-16 | Non-invasive assessment of cell-free circulating mtDNA and copy number open an intriguing spyhole for the diagnosis of NAFLD-HCC in genetically predisposed individuals | Miriam Longo | ![]() |
![]() |
|||
PO1-16 | RIPK3-dependent signalling and crosstalk hepatocytes-macrophages in MASLD progression | André Cardador | ![]() |
![]() |
|||
PO2-16 | The effect of baseline hepatic steatosis on fibrosis changes after SVR in CHC-Genotype 4 patients treated with INF, a 10-year follow-up | Mohamed Elbasiony | ![]() |
![]() |
|||
PO7-16 | Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes | Axel Wester | ![]() |
![]() |
|||
PO5-16 | The role of genetic polymorphism in predicting of metabolic associated fatty liver disease clinical course | Vasyl Prysyazhnyuk | ![]() |
![]() |
|||
PO1-17 | SAMM50 affect mitochondria dynamics in high-fat related non-alcohol steatohepatitis | Wan-Long Chuang | ![]() |
![]() |
|||
PO7-17 | The efficacy of multi-disciplinary lifestyle modifications in Taiwanese non-alcoholic steatohepatitis patients- subgroup analysis of the placebo group patients in a randomized trial | Jee-Fu Huang | ![]() |
![]() |
|||
PO5-17 | Synergistic effect of metabolic dysfunction-associated steatotic liver disease and obesity severity in adolescents on future risk of type 2 diabetes: a cohort study | Resthie R Putri | ![]() |
![]() |
|||
PO6-17 | Effects of sodium-glucose cotransporter 2 inhibitor versus sulfonylurea on nonalcoholic fatty liver disease and diabetes | Yumie TAKESHITA | ![]() |
![]() |
|||
PO2-17 | Assessing the diagnostic accuracy of the fibroScan-AST (FAST) score for high-risk metabolic dysfunction-associated steatohepatitis : a diagnostic accuracy meta-analysis | Muhammed Elfaituri | ![]() |
![]() |
|||
PO3-17 | Transition from non-alcoholic fatty liver disease to steatotic live disease: real-world evidence in a cohort of individuals with type 1 and type 2 diabetes | Tammy Huybrechts | ![]() |
![]() |
|||
PO6-18 | Lipid and carbohydrate metabolism in children with metabolic-associated fatty liver fibrosis | Nataliya Zavhorodnia | ![]() |
![]() |
|||
PO4-18 | Metabolic-associated steatotic liver disease and insulin-related mechanisms: insights from a cluster analysis of the PREVADIAB2 study | Maria Paula Macedo | ![]() |
![]() |
|||
PO5-18 | Diagnostic accuracy of AGILE3 score for the non-invasive identification of patients with steatotic liver disease (SLD) and advanced fibrosis: a systematic review and meta-analysis | Federico Ravaioli | ![]() |
![]() |
|||
PO2-18 | The hepatokine leukocyte cell-derived chemotaxin-2 is elevated in people with impaired glycaemic control and augmented by acute exercise | Buket Engin | ![]() |
![]() |
|||
PO7-18 | Predictive ability of non-invasive fibrosis tests for long-term liver, cardiovascular and kidney outcomes in Europeans with metabolic risk factors from the UK Biobank | Federica Tavaglione | ![]() |
![]() |
|||
PO1-18 | Improvement of HRQoL features and liver status after a 6-month dietary intervention in patients with metabolic dysfunction-associated steatotic liver disease | Gabriele Castelnuovo | ![]() |
![]() |
|||
PO3-18 | The effect of dapagliflozin on fibrosis and inflammation in patients with metabolic dysfunction-associated steatohepatitis | Elena Laura Iliescu | ![]() |
![]() |
|||
PO4-19 | Depression, anxiety, worry and emotional dysregulation in compensated advanced chronic liver disease | Eleonora Maggio | ![]() |
![]() |
|||
PO5-19 | Combining diabetes, sex and menopause as meaningful clinical features associated with NASH and moderate-to-advanced liver fibrosis in uned individuals with class II and III obesity: a retrospective cohort study | Violeta Raverdy | ![]() |
![]() |
|||
PO3-19 | High tyrosine and PLIN2 and low beta-hydroxybutyrate characterize subjects with metabolic dysfunction-associated steatohepatitis (MASH) | Patrizia Infelise | ![]() |
![]() |
|||
PO1-19 | From old to new: assessing the accuracy of non-invasive tests of fibrosis in patients with metabolic associated fatty liver disease and excessive alcohol consumption according to the recent definition | Annalisa Cespiati | ![]() |
![]() |
|||
PO2-19 | Comparison between transient elastography and shear wave elastography for assessment of liver fibrosis in Egyptian patients with NAFLD: a single center experience | Ahmed/ El Fayoumi | ![]() |
![]() |
21-23 September Prague
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|